The previously announced Catalyst HD sales and distribution agreement between C-RAD and Elekta has been expanded to include China, enabling Elekta to offer C-RAD’s surface image-guided radiation therapy (SIGRT) technology for stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), and motion management.

The system, which integrates with Elekta linacs, extends the value of Elekta’s high-definition dynamic radiosurgery (HDRS) solution through complementary capabilities and technologies.

“The Chinese market is one of the fastest-growing radiation therapy markets worldwide, with a huge potential for C-RAD.” Said Tim Thurn, CEO of C-RAD, in a statement. “Together with our partners in China we have established C-RAD as the market leader. Most of the national cancer centers and many customers have adapted our technology to their daily workflow already.”
C-RAD and Elekta engaged in strategic cooperation to provide a comprehensive solution based on C-RAD’s SIGRT solution and Elekta linacs for the North American market in July 2019. The objective is to meet the growing demand of SIGRT in advanced radiation therapy.

"We see the same trend as in Europe and America, that SIGRT is on its way to become a standard of care in China," added Kurt Wang, president C-RAD China.

Anming Gong, executive vice president, Region China at Elekta, said: “The cooperation with C-RAD supports Elekta’s focus on precision radiation medicine for its linac market segment in China. I believe SIGRT can help Chinese cancer clinics to approach precise radiation therapy in a very efficient way.”

C-RAD’s current cooperation with the distributor, Beijing HGPT Technology & Trade Co. Ltd will continue, addressing market opportunities outside the scope of the Elekta agreement.

Business Affairs Homepage